Botulinum Toxin Found Effective as Rescue Therapy for Refractory Digital Ischemia in Systemic Sclerosis: JAMA
Canada: The study indicates that botulinum toxin (BTX) is a safe and effective adjunct treatment for refractory ischemic digital complications, supporting its role as a physician-administered rescue option in autoimmune vasculopathies.
Published in JAMA Dermatology, the systematic review and individual participant data meta-analysis, led by Catherine Zhu from the Faculty of Medicine at McGill University, highlights growing evidence supporting botulinum toxin as a valuable therapeutic tool for severe digital ischemia and ulcers, particularly in systemic sclerosis.
Acute digital ischemia, chronic non-healing ulcers, and gangrene are among the most challenging complications seen in systemic sclerosis and related vasculopathies. These conditions often persist despite standard vasodilator or immunosuppressive regimens, leaving patients with ongoing pain, tissue damage, and risk of amputation. Against this backdrop, BTX has emerged as a potential salvage therapy, but until now, its efficacy and safety profile were not clearly defined.
The review aimed to fill that gap by assessing outcomes from 31 eligible studies involving 119 patients treated with BTX injections for ischemic digital complications. Participants across the included studies had a mean age of 49 years, and three-quarters were female—reflecting the population most affected by autoimmune vasculopathies.
The findings were striking:
- BTX showed high complete response rates: 93.1% for acute ischemia, 90.1% for ischemic ulcers, and 87.5% for digital gangrene.
- A complete response meant full resolution of ischemia or complete healing of digital ulcers, marking meaningful recovery in patients who had limited treatment options.
- Adverse events were infrequent and generally mild.
- The most common side effects were temporary muscle weakness (7.6%) and mild injection-site pain (5.9%).
- No severe or life-threatening reactions were reported, supporting BTX’s safety as an outpatient treatment.
While the analysis did not identify statistically significant predictors of complete response in multivariable models, exploratory Kaplan-Meier analyses suggested that patients with autoimmune etiologies and younger individuals tended to respond more quickly to treatment. However, the authors noted that larger, prospective studies are needed to confirm these associations.
The review highlights the therapeutic potential of BTX in managing severe, refractory digital complications, particularly in systemic sclerosis—one of the most difficult autoimmune diseases to treat. Its minimally invasive nature, rapid onset of action, and outpatient feasibility also give it practical advantages over more resource-intensive treatments.
Despite these promising results, the authors emphasize the need for controlled clinical trials to establish long-term effectiveness, compare BTX head-to-head with standard therapies such as prostaglandins and bosentan, and define optimal dosing and injection techniques. They also highlight the importance of standardizing treatment protocols to ensure consistent outcomes across clinical settings. Future research may also explore adjunct strategies, such as zinc supplementation, which could potentially enhance BTX efficacy.
"Overall, the study provides compelling evidence that botulinum toxin may serve as a valuable adjunctive therapy in the management of refractory digital ischemia, ulcers, and gangrene, offering hope to patients with limited treatment options," the authors concluded.
Reference:
Zhu C, Peri K, Silotch C, et al. Botulinum Toxin for Refractory Digital Ischemia and Ulcers in Systemic Sclerosis: A Systematic Review and Meta-Analysis. JAMA Dermatol. Published online December 10, 2025. doi:10.1001/jamadermatol.2025.4929
Next Story